Ovarian Cancer Clinical Trials in Austin

Showing 81-100 of 191 trials

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

NCT05032040

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.

Ovarian CancerClear Cell CarcinomaEndometrial Cancer+2 more

Xencor, Inc.170 participantsStarted Jul 2022

Prescott, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +14 more locations

Active Not RecruitingPhase 1< 1 mile

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Pancreatic CancerBreast CancerGastric Cancer+13 more

NGM Biopharmaceuticals, Inc130 participantsStarted Mar 2022

Gilbert, Arizona, United States • Los Angeles, California, United States • Sarasota, Florida, United States +6 more locations

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Ovarian Cancer Trials in Other Cities

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

FPA150 in Patients With Advanced Solid Tumors

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

A Study of ZN-c3 in Patients With Ovarian Cancer

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

SGI-110 in Combination With Carboplatin in Ovarian Cancer

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Other Conditions in Austin